Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

被引：3

作者：

Alexander, Thomas ^{[1
]}

Lacayo, Norman J. ^{[2
]}

Pullarkat, Vinod A. ^{[3
]}

Jabbour, Elias J. ^{[4
]}

Khaw, Seong Lin ^{[5
]}

Mullighan, Charles G. ^{[6
,7
]}

Bajel, Ashish ^{[8
]}

Leonard, Jessica ^{[9
]}

Norris, Robin ^{[10
]}

Rubnitz, Jeffrey ^{[11
]}

Vear, Susan I. ^{[12
]}

Schmidt, Michelle ^{[13
]}

Tong, Bo ^{[13
]}

Zhou, Ying ^{[13
]}

Ross, Jeremy A. ^{[13
]}

Rosenwinkel, Lindsey ^{[13
]}

Jacobson, Amanda ^{[13
]}

Kim, Su Young ^{[13
]}

Stock, Wendy ^{[14
]}

机构：

[1] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA

[2] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA

[3] City Hope Natl Med Ctr, Dept Hematol HCT, 1500 E Duarte Rd, Duarte, CA 91010 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[5] Royal Childrens Hosp, Melbourne, Vic, Australia

[6] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN USA

[7] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA

[8] Royal Melbourne Hosp, Melbourne, Vic, Australia

[9] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA

[10] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA

[11] St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA

[12] Nationwide Childrens Hosp, Pediat Hematol & Oncol, Columbus, OH USA

[13] AbbVie Inc, N Chicago, IL USA

[14] Univ Chicago, Dept Med, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-113464

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3966

引用

页数：4

共 50 条

[31] A novel immunotherapy for relapsed/refractory acute lymphoblastic leukemia (ALL)
Saini, Uksha
Hixon, Julie
Rodrigues, Gisele
Foley, Christopher
Chibas, Leniher Castan
Hamilton, Ross
Li, Wenqing
Schafer, Eric S.
Rheingold, Susan
Heffernan, Michael
Breitfeld, Philip
Durum, Scott
Varadhachary, Atul
CANCER RESEARCH, 2023, 83 (07)
[32] Immunotherapy of refractory and relapsed acute lymphoblastic leukemia in childhood and adolescence
Kramm, CM
Kameda, G
Bader, P
Dilloo, D
MONATSSCHRIFT KINDERHEILKUNDE, 2003, 151 (02) : 154 - 165
[33] Use of Bortezomib in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia
Bello, Adriana
Cortez, Rossana
Collazo, Maylu
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S269 - S270
[34] Tailored therapy for relapsed or refractory childhood acute lymphoblastic leukemia
Agthe, AG
Dorffel, W
Neuendank, A
Hartmann, R
Bruhmuller, S
Klumper, E
Pieters, R
Veerman, AJP
Henze, G
DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA II, 1997, 3 : 51 - 57
[35] Importance of blinatumomab in relapsed or refractory acute lymphoblastic leukemia B
Machet, Antoine
Gallego-Hernanz, Pilar
Torregrosa-Diaz, Jose
Leleu, Xavier
HEMATOLOGIE, 2016, 22 (01): : 17 - 18
[36] Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.
Alexander, Thomas
Khaw, Seong Lin
Rubnitz, Jeffrey E.
Vear, Susan I.
Lacayo, Norman James
Schmidt, Michelle
Tong, Bo
Rosenwinkel, Lindsey
Bensman, Lindsey
Verdugo, Maria
Kim, Su Young
Jabbour, Elias
Stock, Wendy
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[37] Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia
Guan, Wei
Jing, Yu
Dou, Liping
Wang, Maoquan
Xiao, Yang
Yu, Li
LEUKEMIA & LYMPHOMA, 2020, 61 (04) : 855 - 861
[38] A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia
Short, Nicholas J.
Jabbour, Elias
Jain, Nitin
Senapati, Jayastu
Nasr, Lewis
Haddad, Fadi G.
Li, Zhenhua
Hsiao, Yu-Chih
Yang, Jun J.
Pemmaraju, Naveen
Ohanian, Maro
Wierda, William G.
Montalban-Bravo, Guillermo
Borthakur, Gautam
Han, Lina
Xiao, Lianchun
Huang, Xuelin
Abramova, Regina
Zhao, Min
Garris, Rebecca
Konopleva, Marina
Ravandi, Farhad
Kantarjian, Hagop
BLOOD ADVANCES, 2024, 8 (04) : 909 - 915
[39] Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma
Candoni, Anna
Lazzarotto, Davide
Petruzzellis, Giuseppe
EXPERT OPINION ON DRUG SAFETY, 2021, 20 (07) : 751 - 756
[40] Nelarabine Combination Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Lymphoma/Leukemia
Shimony, Shai
Liu, Yiwen
Valtis, Yannis K.
Paolino, Jonathan D.
Place, Andrew E.
Brunner, Andrew M.
Weeks, Lachelle D.
Silverman, Lewis B.
Vrooman, Lynda M.
Neuberg, Donna S.
Stone, Richard M.
DeAngelo, Daniel J.
Luskin, Marlise R.
BLOOD, 2022, 140 : 8989 - 8990

← 1 2 3 4 5 →